A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterol

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000622-55

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to assess the mean percentage change from baseline to week 16 in low-density lipoprotein cholesterol (LDL-C) measured using beta quantification with LY3015014 compared with placebo, in patients with primary hypercholesterolemia, when added to statin and diet (or diet alone in statin-intolerant patients) with or without ezetimibe.


Critère d'inclusion

  • Primary hypercholesterolaemia